Immutep Ltd PRRUF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.05
- Day Range
- $0.05–0.05
- 52-Week Range
- $0.04–0.33
- Bid/Ask
- $0.02 / $0.06
- Shares Outstanding
- 1.47B
- Market Cap
- $73.69M
- Volume/Avg
- 11,250 / 394,976
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 27.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3’s ability to stimulate the body’s immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 51
- Website
- https://www.immutep.com
Valuation
|
Metric
|
PRRUF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.11 |
Price/Sales | 27.85 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PRRUF
|
|---|---|
Quick Ratio | 2.91 |
Current Ratio | 2.97 |
Interest Coverage | — |
Quick Ratio
PRRUF
Profitability
|
Metric
|
PRRUF
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PRRUF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|f>d>NFB | LOCK|Dfwt | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?CWcV& | LOCK|pc!@ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|XYrvVM | LOCK|TY& | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#s<m?K%h | LOCK|hV?Y% | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|QG@?Bh@ | LOCK|bN | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|J@<p%?k | LOCK|$<l# | $29B | |||
| Incyte Corp
INCY
| LOCK|v?&#m@j | LOCK|FF> | $24B | |||
| Moderna Inc
MRNA
| LOCK|?r%<y> | LOCK|Y$W | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|$#??jlP | LOCK|$b% | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&WNV@#% | LOCK|!<b | $17B |
United States